|
|
|
|
55 * !
|
Sun, 7/28/2019,
4:00 PM -
5:50 PM
|
CC-110
|
|
Recent Evaluations of Methods for Handling Noncompliance/Dropouts in Clinical Trials for Better Guidance Driven Application — Invited Papers
|
|
Biopharmaceutical Section
|
|
Organizer(s): Xiang Zhang, Eli Lilly and Company
|
|
Chair(s): Xiang Zhang, Eli Lilly and Company
|
|
4:05 PM
|
Principal Component Causal Estimands for Equivalence Trials in the Presence of Intercurrent Events
Wanjie Sun, FDA
|
|
4:25 PM
|
An Evaluation of the Trimmed Mean Approach in Clinical Trials with Dropout
Ming-Dauh Wang, Regeneron ; Craig Mallinckrodt, Biogen; Jiajun Liu, Biogen
|
|
4:45 PM
|
Principal Stratification Approach for Bayesian Sequential Monitoring Design to Address Noncompliance in Clinical Trials
Weining Shen, University of California at Irvine
|
|
5:05 PM
|
Test of Treatment Effect for Binary Composite Endpoint with Missing Components in Clinical Trials
Yanyao Yi, University of Wisconsin at Madison; Ting Ye, University of Wisconsin at Madison; Xiang Zhang, Eli Lilly and Company; Junxiang Luo, Sanofi-Aventis
|
|
5:25 PM
|
Discussant: Ilya Lipkovich, Eli Lilly and Company
|
|
5:45 PM
|
Floor Discussion
|
